United States - English - NLM (National Library of Medicine)

eli lilly and company - olaratumab (unii: tt6hn20mvf) (olaratumab - unii:tt6hn20mvf) - olaratumab 10 mg in 1 ml - lartruvo™ is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (sts) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. this indication is approved under accelerated approval [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. none. risk summary based on animal data and its mechanism of action, lartruvo can cause fetal harm [see clinical pharmacology (12.1)]. there are no available data on lartruvo use in pregnant women. no animal studies using olaratumab have been conducted to evaluate its effect on female reproduction and embryo-fetal development. animal knockout models link disruption of platelet-derived growth factor receptor alpha (pdgfr-α) signaling to adverse effects on embryo-fetal development. administration of an anti-

Canada - English - Health Canada

eli lilly canada inc - olaratumab - solution - 500mg - olaratumab 500mg - antineoplastic agents

Canada - English - Health Canada

eli lilly canada inc - olaratumab - solution - 190mg - olaratumab 190mg - antineoplastic agents

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - olaratumab - sarcoma - antineoplastic agents - lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - olaratumab - solution for infusion - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - olaratumab - solution for infusion - 10mg/1ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly and company - olaratumab - injection - 10 mg/ml

United States - English - NLM (National Library of Medicine)

seroyal usa - lycopodium clavatum spore (unii: c88x29y479) (lycopodium clavatum spore - unii:c88x29y479) - lycopodium clavatum spore 1 [hp_x] - indications for the temporary relief of symptoms associated with gastrointestinal discomforts indications for the temporary relief of symptoms associated with gastrointestinal discomforts directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.